

Phospho-p44/42 MAPK (Erk1/2) (Thr202Tyr204) (D13.14.4E) XP® Rabbit mAb (Sepharose® Bead Conjugate)



Orders ■ 877-616-CELL (2355)
orders@cellsignal.com
Support ■ 877-678-TECH (8324)
info@cellsignal.com
Web ■ www.cellsignal.com

rev. 01/12/16

For Research Use Only. Not For Use In Diagnostic Procedures.

Applications	Species Cross-Reactivity*	Molecular Wt.	Isotype
IP Endogenous	H, M, R, Hm, Mk, Mi, Dm, B, Z, Pg, Sc, (Dg)	44, 42 kDa	Rabbit IgG


Description: This Cell Signaling Technology (CST) antibody is immobilized via covalent binding of primary amino groups to N-hydroxysuccinimide (NHS)-activated Sepharose® beads. Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb (Sepharose® Bead Conjugate) is useful for immunoprecipitation assays. The unconjugated Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb (#4370) reacts with human, mouse, rat, monkey, mink, pig, *Saccharomyces cerevisiae*, *Drosophila melanogaster*, hamster, bovine and zebrafish Phospho-p44/42 MAPK protein. CST expects that Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb (Sepharose® Bead Conjugate) will also recognize phospho MAPK in these species.

Background: Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines (1-3) and is an important target in the diagnosis and treatment of cancer (4).

Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family as well as Mos and Tpl2/Cot. MEK1 and MEK2 are the primary MAPKKs in this pathway (5,6). MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK (7) and the transcription factor Elk-1 (8,9). p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs (10), along with MEK inhibitors such as U0126 and PD98059.

Specificity/Sensitivity: Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb (Sepharose® Bead Conjugate) detects endogenous levels of p44 and p42 MAP kinase (Erk1 and Erk2) when dually phosphorylated at Thr202 and Tyr204 of Erk1 (Thr185 and Tyr187 of Erk2), and singly phosphorylated at Thr202. This antibody does not cross-react with the corresponding phosphorylated residues of either JNK/SAPK or p38 MAP kinases.

Source/Purification: Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Thr202/Tyr204 of human p44 MAP kinase.



Immunoprecipitation of HeLa cell lysates, untreated or TPA-treated, using Rabbit (DA1E) mAb IgG XP® Isotype Control (Sepharose® Bead Conjugate) #3423 (Lanes 1 and 2) and Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb (Sepharose® Bead Conjugate) (Lanes 3 and 4). The blot was probed using Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (E10) Mouse mAb #9106.

Entrez-Gene ID #5595, 5594
UniProt ID #P27361, P28482

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol. Store at -20°C. Do not aliquot the antibody.

*Species cross-reactivity is determined by western blot.

Directions for Use: Add 10 µl of well-vortexed beads to 200 µl of cell lysate at 1 mg/ml in 1X Cell Lysis Buffer (10X) #9803. See protocol for more details.

For product specific protocols please see the web page for this product at www.cellsignal.com.

Please visit www.cellsignal.com for a complete listing of recommended companion products.

Background References:

- (1) Roux, P.P. and Blenis, J. (2004) *Microbiol Mol Biol Rev* 68, 320–44.
- (2) Baccarini, M. (2005) *FEBS Lett* 579, 3271–7.
- (3) Meloche, S. and Pouyssegur, J. (2007) *Oncogene* 26, 3227–39.
- (4) Roberts, P.J. and Der, C.J. (2007) *Oncogene* 26, 3291–310.
- (5) Rubinfeld, H. and Seger, R. (2005) *Mol Biotechnol* 31, 151–74.
- (6) Murphy, L.O. and Blenis, J. (2006) *Trends Biochem Sci* 31, 268–75.
- (7) Dalby, K.N. et al. (1998) *J Biol Chem* 273, 1496–505.
- (8) Marais, R. et al. (1993) *Cell* 73, 381–93.
- (9) Kortenjann, M. et al. (1994) *Mol Cell Biol* 14, 4815–24.
- (10) Owens, D.M. and Keyse, S.M. (2007) *Oncogene* 26, 3203–13.

Sepharose® is a registered trademark of GE Healthcare.